Working... Menu
Trial record 5 of 277 for:    Non-alcoholic Steatohepatitis | United States

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02510599
Recruitment Status : Completed
First Posted : July 29, 2015
Last Update Posted : March 21, 2017
Information provided by (Responsible Party):
Melinta Therapeutics, Inc.

Brief Summary:
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis Drug: solithromycin Phase 2

Detailed Description:
Patients will be administered solithromycin for 13 weeks with regular safety visits and liver biopsies at baseline and after treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Proof of Principle Study to Evaluate the Efficacy and Safety of Solithromycin for the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
Actual Study Start Date : December 2015
Actual Primary Completion Date : January 27, 2017
Actual Study Completion Date : February 28, 2017

Arm Intervention/treatment
Experimental: Solithromycin
Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
Drug: solithromycin
Other Name: CEM-101

Primary Outcome Measures :
  1. To evaluate effects on hepatic histology in patients with NASH [ Time Frame: 13 weeks ]
    Using the Nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS)

Secondary Outcome Measures :
  1. Changes in Steatosis on liver biopsy [ Time Frame: 13 weeks ]
    Graded from 0 to 3

  2. Changes in hepatocellular ballooning score on liver biopsy [ Time Frame: 13 weeks ]
    Graded from 0 to 2

  3. Changes in inflammation on liver biopsy [ Time Frame: 13 weeks ]
    Graded from 0 to 3

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic evidence of NASH based on liver biopsy obtained within 180 days
  • NAS> or = 5
  • Able to swallow capsules intact

Exclusion Criteria:

  • Symptoms of acute liver disease
  • Cirrhosis on liver biopsy
  • Positive HIV or Hepatitis tests
  • Primary Biliary Cirrhosis
  • Poorly controlled diabetes with HgA1C >8.5%
  • ALT >4-fold upper limit of normal
  • QTcF >450 msec
  • CrCl <40 mL/min

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02510599

Layout table for location information
United States, Ohio
Case Western University Hospitals
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Melinta Therapeutics, Inc.
Layout table for investigator information
Study Director: Robert Dobbins, MD, PhD Melinta Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Melinta Therapeutics, Inc. Identifier: NCT02510599     History of Changes
Other Study ID Numbers: CE01-205
First Posted: July 29, 2015    Key Record Dates
Last Update Posted: March 21, 2017
Last Verified: March 2017

Keywords provided by Melinta Therapeutics, Inc.:
Liver disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases
Anti-Bacterial Agents
Anti-Infective Agents